vs
Side-by-side financial comparison of American Assets Trust, Inc. (AAT) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $110.6M, roughly 1.5× American Assets Trust, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 1.8%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -0.1%).
Personal Assets Trust is a large British investment trust. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The chairman is Iain Ferguson CBE.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
AAT vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $110.6M | $168.4M |
| Net Profit | $6.7M | — |
| Gross Margin | — | — |
| Operating Margin | 23.4% | 50.6% |
| Net Margin | 6.1% | — |
| Revenue YoY | 1.8% | 143.7% |
| Net Profit YoY | -16.3% | — |
| EPS (diluted) | $0.08 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $110.6M | — | ||
| Q4 25 | $110.1M | $168.4M | ||
| Q3 25 | $109.6M | $87.3M | ||
| Q2 25 | $107.9M | $82.4M | ||
| Q1 25 | $108.6M | $65.0M | ||
| Q4 24 | $113.5M | $69.1M | ||
| Q3 24 | $122.8M | $51.6M | ||
| Q2 24 | $110.9M | $73.8M |
| Q1 26 | $6.7M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $4.5M | $-31.3M | ||
| Q2 25 | $5.5M | $-12.7M | ||
| Q1 25 | $42.5M | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $16.7M | $-29.5M | ||
| Q2 24 | $11.9M | $-61.9M |
| Q1 26 | — | — | ||
| Q4 25 | 59.4% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 62.6% | — | ||
| Q1 25 | 62.0% | — | ||
| Q4 24 | 61.3% | — | ||
| Q3 24 | 65.5% | — | ||
| Q2 24 | 63.6% | — |
| Q1 26 | 23.4% | — | ||
| Q4 25 | 21.1% | 50.6% | ||
| Q3 25 | 22.6% | -11.4% | ||
| Q2 25 | 24.1% | 8.6% | ||
| Q1 25 | 66.3% | -34.0% | ||
| Q4 24 | 26.5% | -6.4% | ||
| Q3 24 | 30.8% | -31.0% | ||
| Q2 24 | 27.8% | 3.5% |
| Q1 26 | 6.1% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 4.1% | -35.9% | ||
| Q2 25 | 5.1% | -15.4% | ||
| Q1 25 | 39.2% | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 13.6% | -57.2% | ||
| Q2 24 | 10.7% | -83.9% |
| Q1 26 | $0.08 | — | ||
| Q4 25 | $0.06 | $0.32 | ||
| Q3 25 | $0.07 | $-0.16 | ||
| Q2 25 | $0.09 | $-0.06 | ||
| Q1 25 | $0.70 | $-0.21 | ||
| Q4 24 | $0.14 | $-0.14 | ||
| Q3 24 | $0.28 | $-0.15 | ||
| Q2 24 | $0.20 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $118.3M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $-302.0M |
| Total Assets | $2.9B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $118.3M | — | ||
| Q4 25 | $129.4M | $167.9M | ||
| Q3 25 | $138.7M | $92.4M | ||
| Q2 25 | $143.7M | $86.1M | ||
| Q1 25 | $143.9M | $114.6M | ||
| Q4 24 | $425.7M | $144.8M | ||
| Q3 24 | $533.0M | $144.7M | ||
| Q2 24 | $114.9M | $189.3M |
| Q1 26 | — | — | ||
| Q4 25 | $1.7B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.2B | $-302.0M | ||
| Q3 25 | $1.2B | $-451.4M | ||
| Q2 25 | $1.2B | $-433.5M | ||
| Q1 25 | $1.2B | $-426.2M | ||
| Q4 24 | $1.2B | $-388.7M | ||
| Q3 24 | $1.2B | $-370.2M | ||
| Q2 24 | $1.2B | $-344.2M |
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.9B | $465.9M | ||
| Q3 25 | $2.9B | $364.0M | ||
| Q2 25 | $3.0B | $347.1M | ||
| Q1 25 | $3.0B | $324.0M | ||
| Q4 24 | $3.3B | $343.8M | ||
| Q3 24 | $3.4B | $314.1M | ||
| Q2 24 | $3.0B | $352.3M |
| Q1 26 | — | — | ||
| Q4 25 | 1.48× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.72× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 14.5% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $167.1M | $45.2M | ||
| Q3 25 | $40.5M | $-4.3M | ||
| Q2 25 | $49.2M | $-31.4M | ||
| Q1 25 | $36.9M | $-22.6M | ||
| Q4 24 | $207.1M | $-35.0M | ||
| Q3 24 | $52.4M | $-35.3M | ||
| Q2 24 | $59.3M | $-7.2M |
| Q1 26 | — | — | ||
| Q4 25 | $94.9M | — | ||
| Q3 25 | $23.1M | — | ||
| Q2 25 | $28.4M | — | ||
| Q1 25 | $20.4M | — | ||
| Q4 24 | $136.9M | — | ||
| Q3 24 | $28.0M | $-35.5M | ||
| Q2 24 | $43.6M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | 86.2% | — | ||
| Q3 25 | 21.1% | — | ||
| Q2 25 | 26.3% | — | ||
| Q1 25 | 18.8% | — | ||
| Q4 24 | 120.7% | — | ||
| Q3 24 | 22.8% | -68.7% | ||
| Q2 24 | 39.3% | -9.9% |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 65.6% | 0.0% | ||
| Q3 25 | 15.9% | 0.0% | ||
| Q2 25 | 19.3% | 0.0% | ||
| Q1 25 | 15.1% | 0.0% | ||
| Q4 24 | 61.9% | 0.0% | ||
| Q3 24 | 19.9% | 0.3% | ||
| Q2 24 | 14.1% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 8.98× | — | ||
| Q2 25 | 9.01× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.15× | — | ||
| Q2 24 | 4.98× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAT
| Rental income | $104.4M | 94% |
| Other | $6.2M | 6% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
